AstraZeneca's cancer combo wins second nod in one month, this time in lung cancer
Weeks after celebrating the first cancer win for its Imfinzi and Imjudo duo, AstraZeneca is once again breaking out the party hats.
The monoclonal antibody combo scored a label expansion on Thursday in metastatic non-small cell lung cancer (NSCLC) alongside platinum-based chemotherapy. Just last month, the drugs won a nod in unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.